Prolerity Clinical Research Announces New Management Executives
Prolerity Clinical Research is excited to announce the recent appointments of two dynamic individuals to its management team. Erica Prowisor has accepted the role of Executive Vice President of Transformation and Patient Engagement, while Michael Smith joins as Chief Commercial Officer. Prolerity, a leading network of clinical research sites, is known for its commitment to advancing medicine through comprehensive patient engagement and research excellence.
Management Appointments to Drive Growth
CEO of Prolerity, Jeff Williams, expressed his enthusiasm about the new appointments, stating, "I could not be more fortunate to have Erica and Michael join our team. Their extensive backgrounds and innovative thinking are crucial for expanding our site management network to better serve patients and our pharmaceutical and biotech partners." Both Erica and Michael bring a wealth of experience that is expected to enhance Prolerity's growth trajectory significantly.
Erica Prowisor's Experience and Vision
Erica Prowisor, in her new position, is eager to elevate Prolerity's efforts in meeting the needs of patients and their partners in drug development. She emphasizes the importance of innovation in recruitment strategies, aiming to amplify the value provided to clients who depend on their research sites for successful outcomes. Prior to joining Prolerity, Erica held the position of Senior Vice President of Patients and Provider Networks at Science 37, where she demonstrated her leadership in driving patient engagement.
Michael Smith's Strategic Role
Michael Smith shares Erica's enthusiasm for the mission at Prolerity. He highlights the strong reputation of Prolerity's sites in handling challenging research areas, which require precise focus and patient accessibility. Michael previously served as the Chief Commercial Officer at Javara. His broad experience in clinical research operations is set to bolster Prolerity's capabilities in delivering innovative treatments to the market.
Expanding Research Capabilities
Prolerity's growth is further illustrated by its ownership of Tandem Clinical Research, a site renowned for its expertise in NASH/NAFLD and neurodegenerative studies. Tandem has earned accolades for its exceptional management of study feasibility, patient recruitment, and retention. Recently, Tandem has expanded its operations by moving into two newly developed facilities that both emphasize state-of-the-art capabilities for conducting complex trials.
Commitment to Advancing Medicine
At its core, Prolerity Clinical Research is dedicated to improving the quality of life for patients through clinical advancements. The organization strives to engage with diverse populations and supports drug development efforts with a talented team across a growing network of sites. With their expertise in therapeutic coverage across various complex Phase I-III trials—including areas such as gastroenterology, cardiometabolic, and liver diseases—Prolerity is well-positioned to facilitate the development of groundbreaking treatments.
Frequently Asked Questions
What is Prolerity Clinical Research's main focus?
Prolerity Clinical Research focuses on advancing medicine through clinical research, aiming to improve patient quality of life while supporting pharmaceutical and biotech companies.
Who are the new executives at Prolerity?
Erica Prowisor has been appointed as the Executive Vice President of Transformation and Patient Engagement, and Michael Smith as the Chief Commercial Officer.
What areas of research does Prolerity specialize in?
Prolerity specializes in a range of therapeutic areas, particularly in complex Phase I-III trials, including gastroenterology, cardiometabolic, CNS, and liver diseases.
What is Tandem Clinical Research's role within Prolerity?
Tandem Clinical Research operates under Prolerity's network, focusing on NASH/NAFLD and neurodegenerative studies while providing excellence in study feasibility and patient management.
How does Prolerity ensure successful patient engagement?
Prolerity utilizes innovative recruitment strategies and a dedicated team to ensure that it meets the needs of both patients and drug developers effectively.
